{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:37:48Z","timestamp":1789562268593,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270634"],"award-info":[{"award-number":["82270634"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204379"],"award-info":[{"award-number":["82204379"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["No. 25ZR1402578"],"award-info":[{"award-number":["No. 25ZR1402578"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Yttrium-90 (Y-90) selective internal radiation therapy (SIRT) has emerged as an important locoregional treatment for liver and other malignancies. However, despite its expanding clinical application, the global landscape of Y-90 clinical trials has not been systematically characterized. The objective of this study was to systematically characterize the global portfolio of Y-90 clinical trials, compare liver cancer with non\u2013liver cancer indications, and evaluate patterns of result dissemination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional registry-based analysis of all Y-90 clinical trials registered on ClinicalTrials.gov from 2000 to 2025. Trial characteristics, temporal and geographic patterns, methodological features, and reported outcomes were summarized. Comparative analyses were performed between liver cancer and non\u2013liver cancer trials. Registry entries were linked to PubMed to assess publication output.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 373 eligible trials were identified. Most were interventional (86.9%), treatment-focused (93.1%), and single-center (70.1%), with small sample sizes (54.2% enrolled\u2009\u2264\u200930 participants). Nearly half were phase 1\u20132 (47.7%) or phase 2\u20133 (45.8%), with only 6.5% reaching phase 3\u20134. Randomization was reported in 43.5% of trials, but masking was rare (3.4%). Geographically, studies were concentrated in North America (68.4%), with limited representation from Asia (11.5%) despite its high disease burden. Liver cancer accounted for 44.5% of trials and was more likely than non\u2013liver cancer studies to be randomized, advanced-phase, and Asia-based. Among 93 (24.9%) discontinued trials, accrual difficulties were the leading cause (38.7%). Only 68 trials (18.2%) had published results, with efficacy and safety endpoints more consistently reported in liver cancer studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Y-90 research has expanded globally, especially in liver cancer, but trials remain largely small, early phase, and geographically uneven, with limited dissemination. Strengthening methodological rigor through adequately powered multicenter trials, enhancing transparency in result dissemination, and encouraging broader research efforts in high-burden regions such as Asia may help further clarify the optimal role of Y-90 in oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09659-7","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:06:45Z","timestamp":1774598805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Global landscape of yttrium-90 clinical trials: a systematic registry-based analysis"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8203-2390","authenticated-orcid":false,"given":"Qianwen","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3998-9674","authenticated-orcid":false,"given":"Kenan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-1606","authenticated-orcid":false,"given":"Wenyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1259-3593","authenticated-orcid":false,"given":"Yakun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9395-6444","authenticated-orcid":false,"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9794-3192","authenticated-orcid":false,"given":"Zhenguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6508-1038","authenticated-orcid":false,"given":"Zheqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4599-5702","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-3671","authenticated-orcid":false,"given":"Susu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"11","key":"9659_CR1","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2967\/jnumed.116.186346","volume":"59","author":"N Voutsinas","year":"2018","unstructured":"Voutsinas N, Lekperic S, Barazani S, Titano JJ, Heiba SI, Kim E. Treatment of primary liver tumors and liver metastases, Part 1: nuclear medicine techniques. J Nucl Med. 2018;59(11):1649\u201354.","journal-title":"J Nucl Med"},{"key":"9659_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/OTT.S445898","volume":"17","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Yang F, Wang W. Applications of yttrium-90 (90Y) in hepatocellular carcinoma. Onco Targets Ther. 2024;17:149\u201357.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"9659_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000343876","volume":"4","author":"N Khajornjiraphan","year":"2015","unstructured":"Khajornjiraphan N, Thu NA, Chow PK. Yttrium-90 microspheres: a review of its emerging clinical indications. Liver Cancer. 2015;4(1):6\u201315.","journal-title":"Liver Cancer"},{"issue":"19","key":"9659_CR4","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1097\/CM9.0000000000003264","volume":"137","author":"Q Li","year":"2024","unstructured":"Li Q, Ding C, Cao M, Yang F, Yan X, He S, et al. Global epidemiology of liver cancer 2022: an emphasis on geographic disparities. Chin Med J (Engl). 2024;137(19):2334\u201342.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"9659_CR5","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342\u201352.","journal-title":"Hepatology"},{"issue":"10","key":"9659_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4329\/wjr.v16.i10.512","volume":"16","author":"K Hao","year":"2024","unstructured":"Hao K, Paik AJ, Han LH, Makary MS. Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma. World J Radiol. 2024;16(10):512\u201327.","journal-title":"World J Radiol"},{"issue":"2","key":"9659_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497-507.e2.","journal-title":"Gastroenterology"},{"key":"9659_CR8","doi-asserted-by":"publisher","first-page":"1511210","DOI":"10.3389\/fonc.2024.1511210","volume":"14","author":"W Lu","year":"2025","unstructured":"Lu W, Zhang T, Xia F, Huang X, Gao F. Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis. Front Oncol. 2025;14:1511210.","journal-title":"Front Oncol"},{"issue":"1","key":"9659_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12876-022-02396-6","volume":"22","author":"JC Alonso","year":"2022","unstructured":"Alonso JC, Casans I, Gonz\u00e1lez FM, Fuster D, Rodr\u00edguez A, S\u00e1nchez N, et al. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review. BMC Gastroenterol. 2022;22(1):326.","journal-title":"BMC Gastroenterol"},{"key":"9659_CR10","unstructured":"EQUATOR Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)Statement: guidelines for reporting observational studies. Available at: https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/. Accessed on 28 Sept 2025."},{"issue":"4","key":"9659_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/oncolo\/oyad333","volume":"29","author":"M Durando","year":"2024","unstructured":"Durando M, Gopal AK, Tuscano J, Persky D. A systematic review of clinical applications of anti-CD20 radioimmunotherapy for lymphoma. Oncologist. 2024;29(4):278\u201388.","journal-title":"Oncologist"},{"issue":"17","key":"9659_CR12","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/molecules25174012","volume":"25","author":"R Eychenne","year":"2020","unstructured":"Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules. 2020;25(17):4012.","journal-title":"Molecules"},{"issue":"3","key":"9659_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/cancers16030669","volume":"16","author":"SN Mourad","year":"2024","unstructured":"Mourad SN, De la Garza-Ramos C, Toskich BB. Radiation segmentectomy for the treatment of hepatocellular carcinoma: a practical review of evidence. Cancers (Basel). 2024;16(3):669.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"9659_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1148\/radiol.2018171768","volume":"287","author":"RJ Lewandowski","year":"2018","unstructured":"Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050\u20138.","journal-title":"Radiology"},{"key":"9659_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/JHC.S507267","volume":"12","author":"C De la Garza-Ramos","year":"2025","unstructured":"De la Garza-Ramos C, Montazeri SA, LeGout JD, Lewis AR, Frey GT, Paz-Fumagalli R, et al. Radiation Segmentectomy or Ablative External Beam Radiation Therapy as Initial Treatment for Solitary Hepatocellular Carcinoma: A Multicenter Experience. J Hepatocell Carcinoma. 2025;12:553\u20139.","journal-title":"J Hepatocell Carcinoma"},{"issue":"7","key":"9659_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3348\/kjr.2025.0308","volume":"26","author":"IJ Lee","year":"2025","unstructured":"Lee IJ, Kim HC. Optimizing yttrium-90 radioembolization dosimetry for hepatocellular carcinoma: a Korean perspective. Korean J Radiol. 2025;26(7):688\u2013703.","journal-title":"Korean J Radiol"},{"issue":"18","key":"9659_CR17","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1080\/14796694.2025.2524862","volume":"21","author":"CW Too","year":"2025","unstructured":"Too CW, Liang PC, Chotipanich C, Venkatanarashima N, Lo RH, Zhuang KD, et al. Real-world outcomes of selective internal radiation therapy with 90Y resin microspheres in HCC\/mCRC: RESIN registry Asia. Future Oncol. 2025;21(18):2287\u201397.","journal-title":"Future Oncol"},{"issue":"6","key":"9659_CR18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.21037\/hbsn-23-504","volume":"13","author":"P Vigneron","year":"2024","unstructured":"Vigneron P, Franz\u00e8 MS, Chalaye J, Tacher V, Sessa A, Luciani A, et al. Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review. Hepatobiliary Surg Nutr. 2024;13(6):974\u201390.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"Suppl","key":"9659_CR19","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31(Suppl):S228\u201354.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"9659_CR20","first-page":"101","volume":"26","author":"Y Tian","year":"2024","unstructured":"Tian Y, Cao HQ, Zhao DZ. Clinical application of yttrium [90Y] microsphere radioembolization therapy in advanced hepatocellular carcinoma. Modern Med J China. 2024;26(1):101\u20136 (in Chinese).","journal-title":"Modern Med J China"},{"key":"9659_CR21","unstructured":"Top News Daily. \"Injecting a shot\" to treat liver cancer - the first case of yttrium-90 microsphere therapy in Hunan has been successful, and the cost may be around 400,000 yuan. Available at: https:\/\/www.toutiao.com\/article\/7550119618732376586\/?&source=m_redirect. Accessed on 15 Sept 2025. (in Chinese)"},{"key":"9659_CR22","unstructured":"National Bureau of Statistics of China. Households' Income and Consumption Expenditure in 2024. Available at: https:\/\/www.stats.gov.cn\/english\/PressRelease\/202501\/t20250124_1958443.html. Accessed on 17 Jan 2025."},{"key":"9659_CR23","unstructured":"Taihai News. The First Affiliated Hospital of Xiamen University has introduced yttrium-90 resin microspheres for treatment, benefiting liver cancer patients in southern Fujian. Available at: https:\/\/www.taihainet.com\/news\/xmnews\/xmxc\/2026-02-06\/2853363.html. Accessed on 06 Feb 2026. (in Chinese)"},{"key":"9659_CR24","unstructured":"CGTN. China achieves Yttrium-90 production using commercial reactor. Available at:https:\/\/news.cgtn.com\/news\/2025-06-15\/China-achieves-Yttrium-90-production-using-commercial-reactor-1EdHYp0o8pO\/p.html#:~:text=The%20Y-90%20glass%20microspheres%2C%20produced%20through%20irradiation%20at,reactors%20and%20paving%20the%20way%20for%20mass%20production. Accessed on 28 Sept 2025."},{"issue":"11","key":"9659_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2967\/jnumed.120.255745","volume":"62","author":"AA Alsultan","year":"2021","unstructured":"Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, et al. Dose-response and dose-toxicity relationships for glass 90Y radioembolization in patients with liver metastases from colorectal cancer. J Nucl Med. 2021;62(11):1616\u201323.","journal-title":"J Nucl Med"},{"issue":"9","key":"9659_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/RLU.0000000000005198","volume":"49","author":"N Kokabi","year":"2024","unstructured":"Kokabi N, Webster LA, Dabbous H, Shah A, Brandon D, Galt J, et al. Resin-based 90 Y tumor dose as a predictor of duration of response and survival in patients with surgically unresectable hepatocellular carcinoma\u202f: a prospective single-arm study. Clin Nucl Med. 2024;49(9):799\u2013805.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"9659_CR27","doi-asserted-by":"publisher","first-page":"10100","DOI":"10.3390\/curroncol30120734","volume":"30","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, Dabbous HH, Little O, Gbolahan OB, Akce M, Lilly MA, et al. Safety and efficacy of concurrent atezolizumab\/bevacizumab or nivolumab combination therapy with yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma. Curr Oncol. 2023;30(12):10100\u201310.","journal-title":"Curr Oncol"},{"issue":"9","key":"9659_CR28","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/cancers17091494","volume":"17","author":"EL Fite","year":"2025","unstructured":"Fite EL, Makary MS. Advances and emerging techniques in Y-90 radioembolization for hepatocellular carcinoma. Cancers (Basel). 2025;17(9):1494.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"9659_CR29","doi-asserted-by":"publisher","first-page":"109379","DOI":"10.4251\/wjgo.v17.i7.109379","volume":"17","author":"YH Zhu","year":"2025","unstructured":"Zhu YH, Wang MW, Jiao Y, Liu YH, Dong SS. Yttrium-90 microsphere therapy for hepatocellular carcinoma: Clinical efficacy, mechanistic insights, and comparative therapeutic perspectives. World J Gastrointest Oncol. 2025;17(7):109379.","journal-title":"World J Gastrointest Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09659-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09659-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09659-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:35:36Z","timestamp":1778031336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09659-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9659"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09659-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki. As it was a registry-based analysis using publicly available data from ClinicalTrials.gov and PubMed, ethics approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}